ANGLE PLC (LON:AGL, OTCQX:ANPCY) said a 200-patient US clinical verification study has begun.
The company said the combined Parsortix and HyCEAD Ziplex platforms will process a simple blood sample to test for signs of the killer disease.
The team at the University of Rochester Medical Center Wilmot Cancer Institute, New York, hopes to conclude the study by the first quarter of next year.
Success would allow ANGLE to launch a clinical assay to detect ovarian cancer in women with abnormal pelvic masses that delivers very few false positives.
Between 5% and 10% of women will be diagnosed with a pelvic mass during their lifetime, with 13% to 21% diagnosed with ovarian cancer.
A blood test to detect circulating tumour cells prior to surgery would enable women to receive the most appropriate procedures.
ANGLE reckons that the global market size for this clinical application of its technology is worth US$1bn a year.
"We are excited about the start of the full clinical verification study to demonstrate the performance of our ovarian cancer test designed to support the launch of a clinical assay at a clinical laboratory and/or via a commercial partnership," said chief executive Andrew Newland.
ANGLE is the developer of Parsortix, which can detect the tell-tale signs of cancer in the form of circulating tumour cells.
Results from an earlier ovarian cancer study with Rochester showed that deploying Parsortix in harness with HyCEAD Ziplex, which is used to analyse cells, had a high degree of accuracy – better than anything currently on the market.